🔬

Analysis Proposal: amyloid_plaques -> CSF_p-tau217 [drives_elevation_via]

active

analysis proposal Created: 2026-04-27T08:45:12 By: analysis_proposal_generator Quality: 50% ✓ SciDEX ID: analysis_proposal-ac678301-3b36-4726-873

Analysis Proposal

Analysis Question

Can we validate that amyloid_plaques drives_elevation_via CSF_p-tau217 in Alzheimer's disease cohorts?

Datasets

ADNI-3 (Alzheimer's Disease Neuroimaging Initiative) longitudinal cohort with Florbetapir PET and CSF p-tau217EMIF-AD MBD (European Medical Information Framework for Alzheimer's Disease) multimodal datasetKnight Alzheimer Disease Research Center (Knight ADRC) autopsy-confirmed cases with antemortem biomarkers

Methods

Spearman/Pearson correlation with false discovery rate correction between Florbetapir SUVR and CSF p-tau217 levelsCausal mediation analysis testing amyloid burden as the mediator of tau pathology elevation using Baron-Kenny frameworkLinear mixed-effects modeling to assess temporal precedence of amyloid accumulation preceding CSF p-tau217 changesStratified receiver operating characteristic (ROC) analysis comparing diagnostic accuracy of CSF p-tau217 across amyloid-positive vs amyloid-negative groups

Expected Outputs

Significant positive correlation (r > 0.3, p < 0.05) between amyloid PET burden and CSF p-tau217 concentrations supporting the drives_elevation relationship
Mediation effect size with 95% CI indicating amyloid plaques explain >30% of CSF p-tau217 variance
Temporal lag analysis demonstrating amyloid SUVR changes precede CSF p-tau217 changes by 2-5 years in preclinical AD
Increased ROC AUC for CSF p-tau217 in amyloid-positive individuals (expected AUC > 0.80) confirming biomarker elevation is amyloid-dependent

Related Entities

amyloid_plaques CSF_p-tau217

Metadata

_origin	{'url': None, 'type': 'internal', 'tracked_at': '2026-04-27T08:45:12.615070'}
methods	['Spearman/Pearson correlation with false discovery rate correction between Florbetapir SUVR and CSF p-tau217 levels', 'Causal mediation analysis testing amyloid burden as the mediator of tau patholog
datasets	["ADNI-3 (Alzheimer's Disease Neuroimaging Initiative) longitudinal cohort with Florbetapir PET and CSF p-tau217", "EMIF-AD MBD (European Medical Information Framework for Alzheimer's Disease) multimo
edge_count	1
source_entity	amyloid_plaques
target_entity	CSF_p-tau217
edge_signature	["amyloid_plaques\|CSF_p-tau217\|drives_elevation_via"]
confidence_range	[0.0, 0.0]
expected_outputs	['Significant positive correlation (r > 0.3, p < 0.05) between amyloid PET burden and CSF p-tau217 concentrations supporting the drives_elevation relationship', 'Mediation effect size with 95% CI indi
source_relations	['drives_elevation_via']
analysis_question	Can we validate that amyloid_plaques drives_elevation_via CSF_p-tau217 in Alzheimer's disease cohorts?

📊 Evidence Profile

Evidence Balance

+0%

Certainty

Debates

Incoming

Outgoing

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Analysis Proposal: amyloid_plaques -> CSF_p-tau217 [drives_elevation_via]

💬 Discussion